Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.46 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067468 | 0.96 | ACE (0.50) | ACERENKDM4EF2LMNA | |
| SCHEMBL7924504 | 0.96 | ACE (0.50) | ACERENKDM4EF2LMNA | |
| SCHEMBL7381767 | 0.83 | ACE (0.55) | ACERENKDM4EF2LMNA | |
| SCHEMBL7377396 | 0.80 | ACE (0.62) | ACERENKDM4EF2LMNA | |
| SCHEMBL10036511 | 0.79 | MEN1 (0.34) | MAPT | |
| SCHEMBL3048970 | 0.79 | ACE (0.60) | ACERENKDM4EF2LMNA | |
| Miridesap SCHEMBL6788714 | 0.79 | ACE (0.68) | ACEREN | |
| Miridesap SCHEMBL1685022 | 0.79 | ACE (0.68) | ACEREN | |
| Miridesap SCHEMBL1537499 | 0.79 | ACE (0.68) | ACEREN | |
| Miridesap SCHEMBL1537496 | 0.79 | ACE (0.68) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | CARMEL BIOSCIENCES, INC. | 2012-02-16 | — | — | US | disclosed |
| CN-102256970-A | Compositions and methods for treatment of renin-angiotensin aldosterone system (raas)-related disorders | INVASC THERAPEUTICS INC | 2011-11-23 | — | — | CN | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | CARMEL BIOSCIENCES, INC. | 2011-10-20 | — | — | US | disclosed |
| WO-2010096677-A2 | DIHYDROLIPOIC ACID DERIVATIVES COMPRISING NITRIC OXIDE AND THERAPEUTIC USES THEREOF | INVASC THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010045575-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS)-RELATED DISORDERS | INVASC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041025-A1 | Dihydrolipoic Acid Derivatives Comprising Nitric Oxide and Therapeutic Uses Thereof | DLD, LDLR, ALOX15 | ACE 340/4885REN 26/4885KDM4E 4142/4885 |
| US-20110257130-A1 | Compositions and Methods for Treatment of Renin-Angiotensin Aldosterone System (RAAS)- Related Disorders | REN, ACE, AGT | ACE 2/4885REN 1/4885KDM4E 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.